Tianjin Tianyao Pharmaceutical Co (SHSE:600488) ROIC %: 3.74% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600488 Tianjin Tianyao Pharmaceutical Co Ltd SHSE:600488
56 GF Score
Price ¥6.72
GF Value ¥3.59
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Tianjin Tianyao Pharmaceutical Co ROIC %?

Tianjin Tianyao Pharmaceutical Co SHSE:600488 -3.72% 56 ROIC % is 3.74% as of Mar. 2026. GuruFocus rates SHSE:600488 with a GF Score™ of 56/100 and a GF Value™ of ¥3.59 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Tianjin Tianyao Pharmaceutical Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was 3.74%.

As of today (2026-07-15), Tianjin Tianyao Pharmaceutical Co's WACC % is 7.23%. Tianjin Tianyao Pharmaceutical Co's ROIC % is 5.98% (calculated using TTM income statement data). Tianjin Tianyao Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Tianjin Tianyao Pharmaceutical Co  (SHSE:600488) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Tianjin Tianyao Pharmaceutical Co's WACC % is 7.23%. Tianjin Tianyao Pharmaceutical Co's ROIC % is 5.98% (calculated using TTM income statement data). Tianjin Tianyao Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Tianjin Tianyao Pharmaceutical Co ROIC % Related Terms


Tianjin Tianyao Pharmaceutical Co ROIC % Historical Data

* Premium members only.

The historical data trend for Tianjin Tianyao Pharmaceutical Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Tianyao Pharmaceutical Co ROIC % Chart

Tianjin Tianyao Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.24 4.50 4.61 6.47 7.42

Tianjin Tianyao Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.29 4.76 3.25 0.00 3.74

SHSE:600488 vs ZTS, UTHR: ROIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Tianyao Pharmaceutical Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Tianyao Pharmaceutical Co ROIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Tianyao Pharmaceutical Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Tianjin Tianyao Pharmaceutical Co's ROIC % falls into.


SHSE:600488
56GF Score
Tianjin Tianyao Pharmaceutical Co Ltd SHSE:600488
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tianjin Tianyao Pharmaceutical Co ROIC % Calculation

Tianjin Tianyao Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=301.777 * ( 1 - 0.05% )/( (4091.696 + 4038.452)/ 2 )
=301.6261115/4065.074
=7.42 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5698.286 - 1017.127 - ( 638.456 - max(0, 1214.996 - 1804.459+638.456))
=4091.696

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5759.692 - 896.642 - ( 824.598 - max(0, 1167.249 - 2196.154+824.598))
=4038.452

Tianjin Tianyao Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=216.076 * ( 1 - 29.41% )/( (4038.452 + 4118.553)/ 2 )
=152.5280484/4078.5025
=3.74 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5759.692 - 896.642 - ( 824.598 - max(0, 1167.249 - 2196.154+824.598))
=4038.452

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5634.604 - 813.48 - ( 702.571 - max(0, 1003.641 - 2083.307+702.571))
=4118.553

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 3.74% mean?
Tianjin Tianyao Pharmaceutical Co (SHSE:600488) has a ROIC % of 3.74% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Tianjin Tianyao Pharmaceutical Co and its competitors.
Is Tianjin Tianyao Pharmaceutical Co's ROIC % too high?
Tianjin Tianyao Pharmaceutical Co's current ROIC % is 3.74%. The Drug Manufacturers industry median ROIC % is 4.49. Tianjin Tianyao Pharmaceutical Co's value of 3.74% is 16.6% below this industry median. Overall, Tianjin Tianyao Pharmaceutical Co has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Tianyao Pharmaceutical Co's ROIC % compare to ZTS and UTHR?
Tianjin Tianyao Pharmaceutical Co's ROIC % of 3.74% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.49. Tianjin Tianyao Pharmaceutical Co's value of 3.74% is 16.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.49, based on 990 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Tianyao Pharmaceutical Co's current ROIC % of 3.74% is 16.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Tianjin Tianyao Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Tianyao Pharmaceutical Co's current ROIC % is 3.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Tianyao Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Tianyao Pharmaceutical Co (SHSE:600488) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.59, compared to a current price of ¥6.72 — trading 87.2% above its estimated fair value. The current ROIC % is 3.74% and 16.6% below the Drug Manufacturers industry median of 4.49. Tianjin Tianyao Pharmaceutical Co's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Tianjin Tianyao Pharmaceutical Co (SHSE:600488), the current ROIC % is 3.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianjin Tianyao Pharmaceutical Co (SHSE:600488) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Tianyao Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥6.72 is trading 87.2% above its estimated GF Value™ of ¥3.59. GuruFocus considers Tianjin Tianyao Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:600488:

  • ROIC %: 3.74%
  • GF Value™: ¥3.59 vs. price of ¥6.72 (87.2% above fair value)
  • GF Score™: 56/100 with 5 warning signs
  • Industry Position: 16.6% below the Drug Manufacturers median

No single metric tells the full story. See the SHSE:600488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tianjin Tianyao Pharmaceutical Co Business Description

Address No. 221 Huanghai Road, Tianjin Development Zone, Tianjin, CHN, 300457
Tianjin Tianyao Pharmaceutical Co Ltd is a China-based company engages in the development, manufacture, distribution, and export of pharmaceutical products. Its products include corticosteroids and cardiovascular medicine, dexamethasone, and cortisone acetate.
56GF Score

Get the complete analysis for SHSE:600488

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.72
Price
¥3.59
GF Value